Phase II/III Trial of CPT-11/5-FU/l-LV (FOLFIRI) Versus CPT-11/TS-1 (IRIS) as Second Line Chemotherapy of Unresectable Colorectal Cancer
Phase 2
- Conditions
- nresectable Colorectal Cancer
- Registration Number
- JPRN-jRCT1080220199
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd. DAIICHI SANKYO Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Histologically confirmed colorectal cancer
Locally advanced and/or metastatic colorectal cancer
Have prior chemotherapy as first line treatment
Age 20 to 75
Performance status 0 or 1 (ECOG)
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survival
- Secondary Outcome Measures
Name Time Method